Pfizer says a final analysis of its COVID-19 vaccine candidate shows it is 95 per cent effective.
The company said Wednesday it counted 170 cases of the virus among its roughly 43,000 study participants.
It said 162 cases were observed in the placebo group and eight were observed among those who received the vaccine.
“To date, the Data Monitoring Committee for the study has not reported any serious safety concerns related to the vaccine,” said Pfizer in its statement.
The company plans to seek Emergency Use Authorization from the U.S. Food and Drug Administration “within days.”
“The study results mark an important step in this historic eight-month journey to bring forward a vaccine capable of helping to end this devastating pandemic,” said Dr. Albert Bourla, chairman and CEO. “We continue to move at the speed of science to compile all the data collected thus far and share with regulators around the world,”
On Nov. 9, early data from Pfizer suggested the company’s vaccine candidate was more than 90 per cent effective in preventing the virus.
The company expects to produce up to 50 million vaccine doses in 2020 and up to 1.3 billion doses by the end of 2021.
